Document:

NON-EXCLUSIVE
DISTRIBUTION AGREEMENT FOR REGION OF SOUTH FLORIDA

 

This
Amended and Restated Comprehensive Distribution Agreement (this “Agreement”) is made effective as of April 8, 2019
by and between Tauriga Sciences Inc. (OTCQB: TAUG) (“TAUG” or “Tauriga”), a Florida corporation, with
a principal address of 555 Madison Avenue, 5th Floor New York, NY 10022 and IRM Management Corporation (“IRM”),
a Florida Corporation, with its mailing address at 1818 South Australian Ave, Ste. 104 // West Palm Beach, FL, 33409.

 

W
I T N E S S E T H:

 

WHEREAS,
Tauriga is engaged in the manufacture, sale and distribution of a CBD Infused Chewing Sum Product Line (branded as Tauri-GumTM)
(the “Products”) initially focusing on the South Florida Medical Market (specifically:
Chiropractors and Orthopedists) (as defined below),

 

WHEREAS,
Tauriga is the owner or exclusive United States licensee, with authority to sublicense, of the trademarks listed on Exhibit A
hereto, and all service marks, designs, logos, trade names, advertising, commercial symbols and slogans used in connection
with Products (as defined below) (collectively or separately, the “Trademarks”) for the Products and/or
such other products that may become subject to this Agreement;

 

WHEREAS,
IRM is engaged in the management of a large number (more than 50 in total) of medical practices, with a focus on Chiropractors
and Orthopedists, primarily in the U.S. region of Southern Florida (“South FLA”).

 

WHEREAS,
Tauriga and IRM have agreed that the Date of Execution shall be defined as: April 8, 2019.

 

In
consideration of the matters described above, and of the mutual benefits and obligations set forth in this agreement, the parties
agree as follows:

 

I.
RIGHT TO DISTRIBUTE.

 

1.
Tauriga, as the owner and/or exclusive licensee of the Trademarks and all of the other proprietary trade dress, package,
designs, logos related there to (the “Other IP” Inclusive “USPTO filed Trademark for Tauri-GumTM
filed for by Tauriga Sciences Inc. during December 2018) in and to the Products and Tauriga hereby grants to IRM a non-exclusive
right to distribute the Products under the terms of this Agreement in the South FLA Market.

 

2. Tauriga will contemplate
granting to IRM an exclusive license to IRM to market and distribute its Tauri-GumTM product line —
for the South FLA Market — at a later time, should both parties deem it in the best interests of all parties (by
mutual Agreement).

 

3. Tauriga shall make
inventory available to IRM, as requested by IRM to fulfill orders. All net revenue earned & realized by Tauriga shall be deposited
into Tauriga’s dedicated Revenue Intake ACCT at TD Bank.

 

4. The parties acknowledge
and agree that the initial target customers shall be medical practices that believe that a legal CBD Infused Supplement
Gum may be a desirable option for some patients. Tauriga makes the following point(s) clear: The Company shall NOT EVER
make any medical claims or treatment claims with respect to this product — it is simply characterized and classified as
a SUPPLEMENT CHEWING GUM containing 1 Omg of CBD Isolate per serving (1 serving = 1 piece of Gum).

 

    	 	 	 

    	 

    

 

II.
IRM’S OBLIGATIONS

 

1.
IRM shall use reasonable efforts to promote the sale of Products in the South FLA Market and to maintain a business
organization and equipment necessary to function properly in the manufacture (Tauriga’s responsibility), sale
and distribution of Products. IRM may engage such subdistributors, agents or other third parties to assist it in the performance
of this Agreement as IRM deems appropriate; provided that IRM shall be responsible for the conduct and cost of the same.

 

2.
IRM will provide to Tauriga detailed sales reports showing, by customer on a monthly basis: monthly depletions by Product, sales
by channel/accounts and monthly ending inventory,

 

3.
IRM will store, transport and deliver Products at appropriate temperatures in the IRM storage facility, so as to maintain the
high quality of the Products.

 

4.
IRM will provide supplemental material to potential customers — so long as such material(s) are approved by Tauriga (as
well as Tauriga’s specialized CBD Counsel) for the legal protection of all parties.

 

5.
IBM shall maintain inventory levels of Products reasonably necessary to satisfy expected demand.

 

6.
IRM shall materially comply with all laws, rules, regulations, requirements, orders and ordinances now in effect or which may
hereafter be enacted or promulgated applicable to its operations or obligations under this Agreement.

 

7.
IRM covenants, warrants and represents to Tauriga that it is free to enter into this Agreement and is not and shall not be under
any obligation, written or otherwise, to any other party which would prevent IRM from complying with all the terms and conditions
of this Agreement.

 

III.
TAURIGA OBLIGATIONS.

 

1. Marketing
Support. IRM and Tauriga shall from time to time during the term of this Agreement, no less frequently as annually, mutually
determine promotional and marketing programs and expenditures to be undertaken by Tauriga to service and support
the growth and maintenance of sales in the South FLA Market (each, a “Support Budget”). In this regard, the
parties covenant, agree and acknowledge that the cost of any marketing, advertising and promotional fees incurred
by IRM on behalf of Tauriga shall be split as follows:

 

(a)
Fixed fees, i.e., advertising, circular fees — To be Mutually Agreed Upon;

 

(b)
all reset costs — 100% to IRM;

 

(c)
all variable fees and any other costs, including all off-invoice, promos and bill-backs — To be Mutually
Agreed Upon.

 

2.
Materials to be Furnished by Tauriga. Tauriga shall furnish to IRM technical and sales promotional materials, brochures,
bulletins, and specification data on products from time to time. Such materials will be furnished in reasonable quantities
at no cost to IRM.

 

3.
Training. IRM agrees to make available to Tauriga appropriate personnel at reasonable times and places for training on
the Products and distribution techniques preferred by Tauriga. Such training will be provided by Tauriga at Tauriga’s expense,
to assist IRM to fulfill its obligations under this Agreement.

 

4.
Intellectual Property. During the Term, Tauriga hereby grants to IRM a limited, non-transferrable, non-exclusive license
to use the Trademarks and Other IP to IRM solely for use on and in connection with the advertising, promotion, sale and
distribution of the Products in the South FLA Market. Tauriga shall have the right to use IRM’s name and logo on Tauriga’s
website for the purpose of identifying IRM as a distributor of the Products.

 

    	 	-2-	 

    	 

    

 

5.
Tauriga shall fill promptly all orders from IRM for Products and for other items to be provided by Tauriga hereunder.

 

6.
Tauriga shall promptly pay or credit to IRM’s account, when due, not less frequently than monthly, all approved and
verified credits, discounts, allowances, incentive payments, bill backs or other reimbursements due IRM pursuant to any
program to which the parties may agree.

 

7.
Tauriga represents and warrants that:

 

(a)
the Products upon delivery to IRM,

 

(i)
shall be pure and wholesome, fit for human use, merchantable and free from all defects,

 

(ii)
shall, in all instances, comply with all applicable Federal, state or local laws and regulations, in all respects, including without
limitation, beverage quality, labeling, identity, quantity, packaging, and returnable container or deposit requirements;

 

(iii)
shall not be adulterated and misbranded within the meaning of those terms under the Federal Food, Drug and Cosmetic Act,
as amended, and shall not be an article or articles which may not, under the provisions, of said Act, be introduced into interstate
commerce;

 

(iv)
shall not be adulterated or misbranded within the meaning of the Federal Insecticide, Fungicide, and Rodenticide Act, the Federal
Hazardous Substances Act, or any applicable state act or any other applicable Federal, state, or local law or regulation; and

 

(v)
when delivered to IRM, shall have a remaining shelf life of not less than twelve (12) months, the expiration of which
shall be clearly marked on the outside of all cartons and pallets;

 

(b)
it is the owner or exclusive U.S. licensee of the Trademarks and Other IP, that it has the right to license the Trademarks
and Other IP to IRM throughout the Term of this Agreement, and that IRM’s use of the Trademarks and Other IP as provided
by this Agreement will not infringe or violate the rights of any third party; and

 

(c)
it is free to enter into this Agreement and is not under any obligation, written or otherwise, to any other party which would
prevent Tauriga from complying with all the terms and conditions of this Agreement

 

(d)
Tauriga shall replace all Products that, at the time and place of delivery, do not meet the requirements of Section III(7) above,
at Tauriga’s expense, including the amount of IRM’s laid-in cost, at IRM’s option. Tauriga shall
also reimburse IRM for all of IRM’s incidental expenses incurred as a consequence of such Products failure to comply with
Section III(7) above (including but not limited to Products in the hands of IRM or of the retail trade that have purchased
such product from IRM if such Products did not conform to the requirements of Section III(7)) or as a consequence of any other
fault of Tauriga; provided that Tauriga shall not be liable for any of the same to the extent they arise for the actions or inactions
of IRM or the retail trade. The foregoing shall not be construed to entitle IRM to recover lost profits or other consequential
damages resulting from the failure of Products to conforms to the requirements of Section III(7) other than as expressly
set forth above,

 

    	 	-3-	 

    	 

    

 

(e)
Tauriga shall materially comply with all laws, rules, regulations, requirements, orders and ordinances now in effect or which
may hereafter he enacted or promulgated applicable to its operations or obligations under this Agreement.

 

IV.
CONSIDERATION. In addition to any other amounts due to IRM hereunder, Tauriga shall pay and/or deliver the following:

 

1.
Marketing Payment. In consideration for the inherent market leverage afforded by IRM’s extensive
existing relationships with dozens of Chiropractor and Orthopedist firm in the South FLA Market, Tauriga has agreed to
make available to IRM (up to $10,000 in cash), as requested either in partial or one-time cash stipend/payment(s) — whenever
requested by IRM. All cash payment(s) to IRM shall be made via wire transfer(s).

 

2.
Restricted Stock. Tauriga shall issue and deliver Four Hundred and Fifty Thousand (450,000) shares of its unregistered,
common stock (the “TAUG Shares”) to Eric Weinberger. Though some shares of Tauriga’s common stock (the
“Float”) are publicly tradable on the OTCQB under the symbol “TAUG”, these TAUG Shares to be issued hereunder
are not registered for resale and thus the transferability of such shares is “restricted” to certain “exempt
transactions” under the Securities Act of 1933, as amended (the “Securities Act”), including, most notably
the safe harbor sale requirements set forth in Rule 144 promulgated under the Securities Act. IRM, represents and warrant that
it is an “accredited investor” as such term is defined by the Securities Act. These 450,000 Restricted TAUG shares
are Fully earned and vested upon the Execution of this Agreement.

 

IRM
reserves the right to subjugate this issuance into smaller issuances (aggregating 450,000 TAUG Shares), to any 3rd parties (individual
or corporate that it sees fit). This share issuance shall occur within thirty (30) days from date of execution of this Agreement
(however for the purpose of Rule 144, shall revert to or take back to the date at which this Agreement is mutually executed
and deemed “Effective as of that date”). If the Subjugation Instructions or Specific Issuance Instructions
have not been provided to Tauriga within thirty (30) days from date of execution, then the Tauriga commits to issue these 1,000,000
shares within ten (10) business days of the date on which it RECEIVES the specific issuance instructions from IRM.

 

V.
PRODUCT COST — ORDERING PROCEDURES

 

1.
Tauriga has the absolute right to determine what IRM will be charged for each SITU of Product. Tauriga agrees that such pricing
will also be fair and ethical — comparatively to other concurrent business (being transacted in other Markets) by
the Company.

 

2.
Tauriga will give IRM no less than sixty (60) days prior written notice of its intention to change the Cost of any individual
SKU of Products.

 

3.
The payment tends are: IRM has 30 days (from the receipt of customer payment) to transfer all appropriate revenue (portion
contractually owed to Tauriga) to the Company — to its dedicated TD Bank Revenue Intake ACCT.

 

4.
IRM shall order Products from Tauriga from time to time using the purchase order form (to be sent to IRM via email), or such other
form acceptable to the parties. Tauriga shall pay all freight charges for the sale of Products that are delivered to IRM storage
facility in South FLA, FLA or at any other location it may designate within or without the IRM Market.

 

5.
Orders may be placed by fax or by telephone; however, if by telephone, a confirming fax must be sent within 24 hours and referencing
the prior telephone call so as to avoids duplicate orders. All orders placed by IRM for Products during the term of this Agreement
s 1 be subject to Tauriga’s acceptance and the terms of this Agreement. Orders cannot be altered by a different purchase
order form used by IRM or any other party.

 

    	 	-4-	 

    	 

    

 

VI.
TERMINATION

 

1.
Subject to Section VI(5) below, either party shall have the right to terminate this Agreement upon the other party’s
failure to perform any of its material obligations contained in this Agreement, provided however that the non-breaching party
shall first give notice to the breaching party (within ten (10) days of knowledge of the breach) of each such failure and the
breaching party shall have twenty (20) days after receipt of each such notice to cure such failure. If such breach is not cured
within such period, the non-breaching party may terminate this Agreement and seem any other remedies available to it under law
or equity. Notwithstanding the foregoing, in the case of a breach in the payment for Products (not in reasonable dispute by IRM),
IRM shall have only five (5) days after receipt of notice to cure such failure, provided, that, IRM will only be afforded
a maximum of two (2) opportunities to cure payment defaults during each calendar year of the term of this Agreement.

 

2.
In addition, if either Party shall file a voluntary petition in bankruptcy, be declared bankrupt, make an assignment
for the benefit of creditors, or suffer the appointment of a receiver or trustee of its assets or is declared insolvent, that
party shall be in breach of a material obligation of this Agreement, and the non-breaching Party may immediately
terminate this Agreement upon written notice to the breaching Party.

 

3.
Except for Section VI(5) below, nothing contained herein shall be deemed to limit either Party’s right to obtain damages
or equitable relief if either Party shall breach its obligations under this Agreement. All remedies shall be cumulative and are
intended to be, and shall be non- exclusive.

 

4.
Subject to Section VI(5) below, Tauriga may terminate this Agreement without cause, in its sole discretion, at any time upon sixty
(60) days advanced written notice to IRM.

 

5.
Payout.

 

(i)
The Payout shall be due within ninety (90) days of the effective date of such termination. The Payout shall be net of any sums
due to Tauriga as of the effective date of the termination of the Agreement.

 

(ii)
The parties agree that in the event of such a termination, it would be difficult to calculate IRM’s damages and the
liquidated damages set forth in this Section VI(5) are reasonable and do not constitute a penalty. IRM hereby waives to the fullest
extent permitted by law, any and all other claims for damages with respect to the termination of this Agreement subject to this
Section VI(5) of any nature whatsoever, in consideration for the receipt of the Payout.

 

6.
The parties acknowledge and agree that this Agreement may be terminated only in accordance with the terms of this
Section VI and Section XII. Any termination not permitted hereunder or under Section XII shall be deemed null and void.

 

    	 	-5-	 

    	 

    

 

VII.
IRM AS AN INDEPENDENT CONTRACTOR. IRM and Tauriga shall remain independent contractors and nothing herein shall be interpreted
as the parties hereto acting in concert or as joint ventures or partners. Except as specifically set forth herein, IRM
and Tauriga do not convey to each other any property interest in the other’s corporate name, Trademarks or intellectual
property. IRM has not paid nor agreed to pay any fee or other consideration for the rights conferred on it hereby, and agrees
that it is not a franchisee within the meaning of, and hereby expressly waives, to the fullest extent permitted by law, the benefits
of and any claim under, any statute or rule regulating franchises, distribution agreements or similar hatters, or any so- called
franchisee or distributor protection, or business opportunity or dealership, laws.

 

VIII.
ASSIGNMENT. This Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of each
party. This Agreement is not assignable by either party without the prior express written consent of the other party, and any
purported assignment without such consent shall be null and void, Notwithstanding the foregoing, IRM may assign this Agreement
to a subsidiary of or other affiliated entity in common control with IRM without Tauriga’s consent upon written notice to
Tauriga of such assignment, so long as IRM remains primarily liable for its obligations.

 

IX.
INDEMNIFICATION

 

1.
IRM shall indemnify, hold harmless and defend Tauriga, its affiliates and their respective officers, directors and employees from
any and all loss, liability, claim, damage, including but not limited to, claims of injury or death to person or damage to property,
and expenses (including reasonable attorney’s fees) which they, or any of them, may suffer or incur as a result or arising
out of the distribution or other activities of IRM under this Agreement including any intentional or negligent act/or omission
to act by IRM or any of its employees, agents officers or directors.

 

2.
Tauriga shall indemnify, hold harmless and defend IRM, its affiliates and their respective officers, directors and employees from
any and all loss, liability, claim, damage, including but not limited to, claims of injury or death to person or damage to property,
and expenses (including reasonable attorney’s fees) which they, or any of them, may suffer or incur as a result or arising
out of the breach of any representation or obligation under this Agreement, and/or with respect to the Products, or the manufacturing,
distribution or other activities of Tauriga under this Agreement, including any intentional or negligent act/or omission to act
by Tauriga or any of its employees, agents, officer or directors.

 

3.
In any claim for indemnification under this Agreement, the party seeking indemnification (the “Indemnitee”)
shall give written notice to the other party against which such indemnification is sought (the “Indemnitor”)
with reasonable promptness after notice of any claim or suit involving, or which could involve, an indemnifiable claim under
this Agreement. Notwithstanding anything to the contrary provided in this Agreement, in any action in which such third party claims
are asserted against the Indemnitee (whether or not such claim is covered by insurance), the Indemnitee shall assert his,
her or its right of indemnification against the Indemnitor in that action, by whatever procedural options are available to the
Indemnitee. If the Indemnitor has acknowledged in writing its obligation to indemnify the Indemnitee in respect of third party
claim, the Indemnitee shall not settle or otherwise compromise such claim without the prior written consent of the Indemnitor,
which consent shall not be unreasonably withheld, unless this condition violates the provisions of the Indemnitor’s liability
insurance policy. The parties shall cooperate with one another in the defense of any indemnifiable claim.

 

    	 	-6-	 

    	 

    

 

X.
INSURANCE. During the term of this Agreement Tauriga shall provide, and keep in force, at its sole expense, a product liability
insurance policy, with limits of liability of not less than $2,000,000 and not more than $5,000,000 for product liability claims,
which shall name the other party as an additional insured. Such policy shall provide that it may not be cancelled without at least
thirty (30) days prior written notice to each party as the case may be, if at any point in this Agreement, said policies
lapses on with respect to any Products manufactured or supplied to IRM for distribution, the lapse will be considered a material
breach.

 

XI.
AUTHORITY. The undersigned persons executing this Agreement hereby certify that they are duly authorized and empowered
by the governing board of their respective company or corporation, and the articles and bylaws and/or operating agreement,
as applicable, thereof, to execute and deliver this Agreement.

 

XII.
FORCE MAJEURE

 

1.
A party’s obligation hereunder shall be suspended if such party is prevented from performing its obligations as a result
of fire, flood, explosion, accident, breakdown of machinery, product tampering by third parties, governmental acts, laws or regulations
(other than government action in response to public health violations by such party), war, terrorism, labor difficulties, any
act of God or any other cause not within such party’s control, which, by the exercise of reasonable due diligence, such
party is not able to avoid or overcome within a reasonable period of time (each, a “Force Majeure”).

 

2.
If IRM is the party that is unable to perform its obligations under this Agreement during the event of Force Majeure, upon the
occurrence of a Force Majeure event, IRM shall assess in good faith, the projected duration of the Force Majeure event.
If IRM reasonably anticipates the duration will be sixty (60) days or less, IRM will notify Tauriga in writing of the anticipated
duration, and Tauriga may distribute its products through another distribution channel. Tauriga shall be required to resume distribution
of its products through IRM seven (7) days after IRM notifies Tauriga in writing that IRM is able to commence its distribution
operations.

 

3.
Notwithstanding any other provision of this Agreement, if a Force Majeure event continues for more than ninety (90) days, the
party whose performance is not impaired by such Force Majeure event may terminate this Agreement upon written notice to the other
party, and 5uch termination shall be with cause.

 

XIII.
WAIVER. Failure of either party at any time to require performance by the other party of any provision of this agreement shall
in no way affect the full right to require such performance at any time thereafter. The waiver of either party to any provision
of this Agreement shall not be taken or held to be a waiver of any succeeding breach of such provisions or as a waiver of the
provision itself.

 

XIV.
GOVERNING LAW, JURISDICTION. The parties agree that this Agreement shall be governed by, construed, and enforced in accordance
with the laws of the State of New York, without regard to principles of conflicts of laws. EACH OF THE PARTIES CONSENTS
THAT ANY LEGAL ACTION OR PROCEEDING AGAINST IT UNDER, ARISING OUT OF OR IN ANY MANNER RELATING TO THIS AGREEMENT, SHALL BE BROUGHT
EXCLUSIVELY IN ANY COURT OF THE STATE OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW
YORK, IN EACH CASE, IN THE COUNTY OF NEW YORK. EACH OF THE PARTIES EXPRESSLY AND IRREVOCABLY CONSENTS AND SUBMITS
TO THE PERSONAL JURISDICTION OF ANY OF SUCH COURTS IN ANY SUCH ACTION OR PROCEEDINGS. EACH OF THE PARTIES AGREES THAT PERSONAL
JURISDICTION OVER IT MAY BE OBTAINED BY THE DELIVERY OF A SUMMONS (POSTAGE PREPAID) IN ACCORDANCE WITH THE PROVISIONS OF
SECTION XX OF THIS AGREEMENT, ASSUMING DELIVERY OF THE SUMMONS IN ACCORDANCE WITH THE PROVISIONS OF SECTION 19 OF THIS
AGREEMENT, EACH OF THE PARTIES HEREBY EXPRESSLY AND IRREVOCABLY WAIVES ANY ALLEGED LACK OF PERSONAL JURISDICTION, IMPROPER
VENUE OF FORUM NON CONVENIENS OR ANY SIMILAR BASIS. EACH PARTY WAIVES TRIAL BY JURY IN ANY PROCEEDING HEREUNDER.

 

    	 	-7-	 

    	 

    

 

XV.
ARBITRATION. All disputes under this Agreement that cannot be resolved by the parties shall be submitted to arbitration
under the rules and regulations of the American Arbitration Association. Either party may invoke this paragraph after providing
thirty (30) days’ written notice to the other party. All costs of arbitration shall be divided equally between the parties.
Any award may be enforced by a court of law.

 

XVI.
PRESS RELEASES. IRM acknowledges that Tauriga may be required to issue press releases from time to time as a reporting
company subject to the requirements of the Securities Exchange Act of 1934 Act (the “34 Act”) regarding material events
relating to any matter directly or indirectly pertaining to the Agreement, the results therefrom and/or the course of conduct
of the Parties relating thereto. In this regard, Tauriga acknowledges and agrees that it shall not issue any press release referring,
directly or indirectly, to the Agreement, IRM and/or any of its affiliates, without the prior written approval of IRM.

 

XVII.
ENTIRE AGREEMENT. This Agreement shall constitute
the entire agreement between the parties and any prior understanding or representation of any hind preceding the date of this
agreement shall not be binding upon either party except to the extent incorporated in this Agreement.

 

XVIII.
MODIFICATION OF AGREEMENT. Any modification of this Agreement or additional obligation assumed by either party in connection
with this Agreement shall be binding only if evidenced in writing and signed by each party or an authorized representative of
each party.

 

XIX.
EFFECT OF PARTIAL INVALIDITY. The invalidity of any portion of this Agreement will not and shall not be deemed to affect the
validity of any other provision. In the event that any provision of this Agreement is held to be invalid, the parties agree
that the remaining provisions shall be deemed to be in full force and effect as if they had been executed by both parties subsequent
to the expungement of the invalid provision.

 

XX.
NOTICES. Any notice provided for or concerning this Agreement shall be in writing and shall be deemed sufficiently given
when sent a nationally recognized overnight courier service to the persons and address as set forth below:

 

	For
    E&M:	IRM
    Management LLC	 
	 	1818
    South Australian Ave, Ste. 104 	 
	 	West
    Palm Beach, FLA 33409	 
	 	Attn:
    Eric Weinberger	 
	 	 	 
	For
    Tauriga:	Tauriga
    Sciences Inc.	 
	 	555
    Madison Avenue, 5th Floor 	 
	 	New
    York, NY 10022	 
	 	Attn:
    Seth M. Shaw, CEO	 

 

XXI.
PARAGRAPH HEADINGS. The titles to the paragraphs of this Agreement are solely for the convenience of the parties and
shall not be used to explain, modify, simplify, or aid in the interpretation of the provisions of this Agreement.

 

XXII.
COUNTERPARTS AND FAX SIGNATURES. This Agreement may be executed in two or more counterparts, each of which shall be deemed
an original, and all such counterparts shall constitute a single instrument. The parties agree that a facsimile or digital
signature of a party hereto shall be deemed to be as legally effective and binding as a signed original; provided, however,
any party providing a fax or digital signature shall be required to promptly forward a signed original to any requesting party.

 

    	 	-8-	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have duly executed this Agreement the day and year first above written.

 

	 	Tauriga
    Sciences Inc.
	 	 	 
	 	By:	 
	 	Name:
    	Seth
    M. Shaw
	 	Title:	Chief
    Executive Officer,
	 	 	 
	 	IRM
    Management Corporation
	 	 	 
	 	By:	 
	 	Name:
    	Eric
    Weinberger
	 	Title:
    	President

 

    	 	-9-	 

    	 

    

 

PEROSNAL
BIO for Mr. Eric Weinberger (PRESIDENT of IRM):

 

Eric
Weinberger was raised in South Florida. He is the son of a cardiothoracic surgeon and has been involved in healthcare ever since
lie was a young boy. He graduated from the Benjamin School in 1993 and then went on to James Madison University on tennis scholarship.
Eric graduated with a B.S. in health services administration in 1997 and was recruited by HCA to world in the administrative department
at JFI€ Medical Center. In 1999, Eric transitioned into physician practice management and marketing where he could use his
relationships with physicians, who he had grown up with, along with its college degree to help physicians improve the overall
efficiency and profitability. Eric has worked with outpatient imaging center as well and developed a strong network of physicians,
hospitals, ambulatory surgery centers, outpatient imaging center and chiropractors. In 2006, he obtained his MBA from the University
of Miami and was recruited to work with an orthopedic and neurosurgical group in South Florida. Eric has since grown this practice
to 5 locations in South Florida, 2 in Central Florida and 2 in South Carolina.

 

TRADEMARKS

 

“Tauri-Gum”
and all associated trademarks

 

    	 	-10-THIS
NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES
SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”)

 

US
$300,000.00

 

TAURIGA
SCIENCES, INC.

8%
CONVERTIBLE REDEEMABLE NOTE

DUE MARCH 14, 2020

 

FOR
VALUE RECEIVED, Tauriga Sciences, Inc. (the “Company”) promises to pay to the order of GS CAPITAL PARTNERS, LLC and
its authorized successors and permitted assigns (“Holder”), the aggregate principal face amount of Three Hundred
Thousand Dollars exactly (U.S. $300,000.00) on March 14, 2020 (“Maturity Date”) and to pay interest on the
principal amount outstanding hereunder at the rate of 8% per annum commencing on March 14, 2019. The Company acknowledges this
Note was issued with a $20,000 original issue discount (OID) and as such the purchase price was $280,000.00. The interest will
be paid to the Holder in whose name this Note is registered on the records of the Company regarding registration and transfers
of this Note. The principal of, and interest on, this Note are payable at 30 Broad Street, Suite 1201 New York, NY 10004, initially,
and if changed, last appearing on the records of the Company as designated in writing by the Holder hereof from time to time.
The Company will pay each interest payment and the outstanding principal due upon this Note before or on the Maturity Date, less
any amounts required by law to be deducted or withheld, to the Holder of this Note by check or wire transfer addressed to such
Holder at the last address appearing on the records of the Company. The forwarding of such check or wire transfer shall constitute
a payment of outstanding principal hereunder and shall satisfy and discharge the liability for principal on this Note to the extent
of the sum represented by such check or wire transfer. Interest shall be payable in Common Stock (as defined below) pursuant to
paragraph 4(b) herein.

 

This
Note is subject to the following additional provisions:

 

1.
This Note is exchangeable for an equal aggregate principal amount of Notes of different authorized denominations,
as requested by the Holder surrendering the same.

 

    	 	 	 

    	 

    

 

No
service charge will be made for such registration or transfer or exchange, except that Holder shall pay any tax or other governmental
charges payable in connection therewith.

 

2.
The Company shall be entitled to withhold from all payments any amounts required to be withheld under applicable laws.

 

3.
This Note may be transferred or exchanged only in compliance with the Securities Act of 1933, as amended (“Act”)
and applicable state securities laws. Any attempted transfer to a non-qualifying party shall be treated by the Company as void.
Prior to due presentment for transfer of this Note, the Company and any agent of the Company may treat the person in whose name
this Note is duly registered on the Company’s records as the owner hereof for all other purposes, whether or not this Note
be overdue, and neither the Company nor any such agent shall be affected or bound by notice to the contrary. Any Holder of this
Note electing to exercise the right of conversion set forth in Section 4(a) hereof, in addition to the requirements set forth
in Section 4(a), and any prospective transferee of this Note, also is required to give the Company written confirmation that this
Note is being converted (“Notice of Conversion”) in the form annexed hereto as Exhibit A. The date of
receipt (including receipt by telecopy) of such Notice of Conversion shall be the Conversion Date.

 

4.
(a) The Holder of this Note is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal
face amount of this Note then outstanding into shares of the Company’s common stock (the “Common Stock”)
at a price (“Conversion Price”) for each share of Common Stock equal to 68% of the lowest daily
VWAP of the Common Stock (32% discount) as reported on the National Quotations Bureau OTC Markets exchange which the Company’s
shares are traded or any exchange upon which the Common Stock may be traded in the future (“Exchange”), for
the fifteen prior trading days including the day upon which a Notice of Conversion is received by the Company
or its transfer agent (provided such Notice of Conversion is delivered by fax or other electronic method of communication to the
Company or its transfer agent after 4 P.M. Eastern Standard or Daylight Savings Time if the Holder wishes to include the same
day closing price). If the shares have not been delivered within 3 business days, the Notice of Conversion may be rescinded. Such
conversion shall be effectuated by the Company delivering the shares of Common Stock to the Holder within 3 business days of receipt
by the Company of the Notice of Conversion. Accrued but unpaid interest shall be subject to conversion. No fractional shares or
scrip representing fractions of shares will be issued on conversion, but the number of shares issuable shall be rounded to the
nearest whole share. To the extent the Conversion Price of the Company’s Common Stock closes below the par value
per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the
lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event
the Company experiences a DTC “Chill” on its shares, the conversion price shall be decreased to 58% instead of 68%
while that “Chill” is in effect. In no event shall the Holder be allowed to effect a conversion if such conversion,
along with all other shares of Company Common Stock beneficially owned by the Holder and its affiliates would exceed 9.9% of the
outstanding shares of the Common Stock of the Company.

 

    	 	 	 

    	 

    

 

(b)
Interest on any unpaid principal balance of this Note shall be paid at the rate of 8% per annum. Interest shall be paid by the
Company in Common Stock (“Interest Shares”). Holder may, at any time, send in a Notice of Conversion to the Company
for Interest Shares based on the formula provided in Section 4(a) above. The dollar amount converted into Interest Shares shall
be all or a portion of the accrued interest calculated on the unpaid principal balance of this Note to the date of such notice.

 

(c)
During the first six months this Note is in effect, the Company may redeem this Note by paying to the Holder an amount as follows:
(i) if the redemption is within the first 90 days this Note is in effect, then for an amount equal to 120% of the unpaid principal
amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day
this Note is in effect, but less than the 180th day this Note is in effect, then for an amount equal to 133% of the unpaid principal
amount of this Note along with any accrued interest. This Note may not be redeemed after 180 days. The redemption must be closed
and paid for within 3 business days of the Company sending the redemption demand or the redemption will be invalid and the Company
may not redeem this Note. Such redemption must be closed and funded within 3 days of giving notice of redemption of the right
to redeem shall be null and void.

 

(d)
Upon (i) a transfer of all or substantially all of the assets of the Company to any person in a single transaction or series of
related transactions, (ii) a reclassification, capital reorganization or other change or exchange of outstanding shares of the
Common Stock, other than a forward or reverse stock split or stock dividend, or (iii) any consolidation or merger of the Company
with or into another person or entity in which the Company is not the surviving entity (other than a merger which is effected
solely to change the jurisdiction of incorporation of the Company and results in a reclassification, conversion or exchange of
outstanding shares of Common Stock solely into shares of Common Stock) (each of items (i), (ii) and (iii) being referred to as
a “Sale Event”), then, in each case, the Company shall, upon request of the Holder, redeem this Note in cash for 150%
of the principal amount, plus accrued but unpaid interest through the date of redemption, or at the election of the Holder, such
Holder may convert the unpaid principal amount of this Note (together with the amount of accrued but unpaid interest) into shares
of Common Stock immediately prior to such Sale Event at the Conversion Price.

 

(e)
In case of any Sale Event (not to include a sale of all or substantially all of the Company’s assets) in connection with
which this Note is not redeemed or converted, the Company shall cause effective provision to be made so that the Holder of this
Note shall have the right thereafter, by converting this Note, to purchase or convert this Note into the kind and number of shares
of stock or other securities or property (including cash) receivable upon such reclassification, capital reorganization or other
change, consolidation or merger by a holder of the number of shares of Common Stock that could have been purchased upon exercise
of the Note and at the same Conversion Price, as defined in this Note, immediately prior to such Sale Event. The foregoing provisions
shall similarly apply to successive Sale Events. If the consideration received by the holders of Common Stock is other than cash,
the value shall be as determined by the Board of Directors of the Company or successor person or entity acting in good faith.

 

    	 	 	 

    	 

    

 

5.
No provision of this Note shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the
principal of, and interest on, this Note at the time, place, and rate, and in the form, herein prescribed.

 

6.
The Company hereby expressly waives demand and presentment for payment, notice of non-payment, protest, notice of protest, notice
of dishonor, notice of acceleration or intent to accelerate, and diligence in taking any action to collect amounts called for
hereunder and shall be directly and primarily liable for the payment of all sums owing and to be owing hereto.

 

7.
The Company agrees to pay all costs and expenses, including reasonable attorneys’ fees and expenses, which may be incurred
by the Holder in collecting any amount due under this Note.

 

8.
If one or more of the following described “Events of Default” shall occur:

 

(a)
The Company shall default in the payment of principal or interest on this Note or any other note issued to the Holder by the Company;
or

 

(b)
Any of the representations or warranties made by the Company herein or in any certificate or financial or other written statements
heretofore or hereafter furnished by or on behalf of the Company in connection with the execution and delivery of this Note, or
the Securities Purchase Agreement under which this note was issued shall be false or misleading in any respect; or

 

(c)
The Company shall fail to perform or observe, in any respect, any covenant, term, provision, condition, agreement or obligation
of the Company under this Note or any other note issued to the Holder; or

 

(d)
The Company shall (1) become insolvent; (2) admit in writing its inability to pay its debts generally as they mature; (3) make
an assignment for the benefit of creditors or commence proceedings for its dissolution; (4) apply for or consent to the appointment
of a trustee, liquidator or receiver for its or for a substantial part of its property or business; (5) file a petition for bankruptcy
relief, consent to the filing of such petition or have filed against it an involuntary petition for bankruptcy relief, all under
federal or state laws as applicable; or

 

(e)
A trustee, liquidator or receiver shall be appointed for the Company or for a substantial part of its property or business without
its consent and shall not be discharged within sixty (60) days after such appointment; or

 

(f)
Any governmental agency or any court of competent jurisdiction at the instance of any governmental agency shall assume custody
or control of the whole or any substantial portion of the properties or assets of the Company; or

 

    	 

    	 	 	 

    

 

(g)
One or more money judgments, writs or warrants of attachment, or similar process, in excess of fifty thousand dollars
($50,000) in the aggregate, shall be entered or filed against the Company or any of its properties or other assets and
shall remain unpaid, unvacated, unbonded or unstayed for a period of fifteen (15) days or in any event later than five (5)
days prior to the date of any proposed sale thereunder; or

 

(h)
The Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has
entered and failed to cure such default within the appropriate grace period; or

 

(i)
The Company shall have its Common Stock delisted from an exchange (including the OTC Market Exchange) or, if the Common Stock
trades on an exchange, then trading in the Common Stock shall be suspended for more than 10 consecutive days or ceases to file
its 1934 act reports with the SEC;

 

(j)
If a majority of the members of the Board of Directors of the Company on the date hereof are no longer serving as members of the
Board;

 

(k)
The Company shall not deliver to the Holder the Common Stock pursuant to paragraph 4 herein without restrictive legend within
3 business days of its receipt of a Notice of Conversion; or

 

(l)
The Company shall not replenish the reserve set forth in Section 12, within 3 business days of the request of the Holder.

 

(m)
The Company shall not be “current” in its filings with the Securities and Exchange Commission;

 

(n)
The Company shall lose the “bid” price for its stock in a market (including the OTC marketplace or other exchange);
or

 

Then,
or at any time thereafter, unless cured within 5 days, and in each and every such case, unless such Event of Default shall
have been waived in writing by the Holder (which waiver shall not be deemed to be a waiver of any subsequent default) at the
option of the Holder and in the Holder’s sole discretion, the Holder may consider this Note immediately due and
payable, without presentment, demand, protest or (further) notice of any kind (other than notice of acceleration), all of
which are hereby expressly waived, anything herein or in any note or other instruments contained to the contrary
notwithstanding, and the Holder may immediately, and without expiration of any period of grace, enforce any and all of the
Holder’s rights and remedies provided herein or any other rights or remedies afforded by law. Upon an Event of Default,
interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current
law, then at the highest rate of interest permitted by law. In the event of a breach of Section 8(k) the penalty shall be
$250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company.
This penalty shall increase to $500 per day beginning on the 10th day. The penalty for a breach of Section 8(n) shall be an
increase of the outstanding principal amounts by 20%. In case of a breach of Section 8(i), the outstanding principal due
under this Note shall increase by 50%. If this Note is not paid at maturity, the outstanding principal due under this Note
shall increase by 10%. Further, if a breach of Section 8(m) occurs or is continuing after the 6 month anniversary of the
Note, then the Holder shall be entitled to use the lowest closing bid price during the delinquency period as a base price for
the conversion. For example, if the lowest closing bid price during the delinquency period is $0.01 per share and the
conversion discount is 50% the Holder may elect to convert future conversions at $0.005 per share.

 

    	 	 	 

    	 

    

 

If
the Holder shall commence an action or proceeding to enforce any provisions of this Note, including, without limitation, engaging
an attorney, then if the Holder prevails in such action, the Holder shall be reimbursed by the Company for its attorneys’
fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.

 

Make-Whole
for Failure to Deliver Loss. At the Holder’s election, if the Company fails for any reason to deliver to the Holder the
conversion shares by the by the 3rd business day following the delivery of a Notice of Conversion to the Company and if the Holder
incurs a Failure to Deliver Loss, then at any time the Holder may provide the Company written notice indicating the amounts payable
to the Holder in respect of the Failure to Deliver Loss and the Company must make the Holder whole as follows:

 

Failure
to Deliver Loss = [(High trade price at any time on or after the day of exercise) x (Number of conversion shares)]

 

The
Company must pay the Failure to Deliver Loss by cash payment, and any such cash payment must be made by the third business day
from the time of the Holder’s written notice to the Company.

 

9.
In case any provision of this Note is held by a court of competent jurisdiction to be excessive in scope or otherwise invalid
or unenforceable, such provision shall be adjusted rather than voided, if possible, so that it is enforceable to the maximum extent
possible, and the validity and enforceability of the remaining provisions of this Note will not in any way be affected or impaired
thereby.

 

10.
Neither this Note nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument signed
by the Company and the Holder.

 

11.
The Company represents that it is not a “shell” issuer and has never been a “shell” issuer or that if
it previously has been a “shell” issuer that at least 12 months have passed since the Company has reported form 10
type information indicating it is no longer a “shell issuer. Further. The Company will instruct its counsel to either (i)
write a 144 opinion to allow for salability of the conversion shares or (ii) accept such opinion from Holder’s counsel.

 

    	 	 	 

    	 

    

 

12.
The Company shall issue irrevocable transfer agent instructions reserving 8,000,000 shares of its Common Stock for
conversions under this Note equal to one and a half times the discounted value of the Note (the “Share Reserve”) within
5 days from the date of execution. Upon full conversion of this Note, any shares remaining in the Share Reserve shall be
cancelled. The Company shall pay all transfer agent costs associated with issuing and delivering the share certificates to
Holder. If such amounts are to be paid by the Holder, it may deduct such amounts from the Conversion Price. The company
should at all times reserve a minimum of one and a half times the amount of shares required if the note would be fully
converted. The Holder may reasonably request increases from time to time to reserve such amounts. The Company will instruct
its transfer agent to provide the outstanding share information to the Holder in connection with its conversions.

 

13.
The Company will give the Holder direct notice of any corporate actions, including but not limited to name changes, stock splits,
recapitalizations etc. This notice shall be given to the Holder as soon as possible under law.

 

14.
If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury,
the applicable provision shall automatically be revised to equal the maximum rate of interest or other amount deemed interest
permitted under applicable law. The Company covenants (to the extent that it may lawfully do so) that it will not seek to claim
or take advantage of any law that would prohibit or forgive the Company from paying all or a portion of the principal or interest
on this Note.

 

15.
This Note shall be governed by and construed in accordance with the laws of New York applicable to contracts made and wholly to
be performed within the State of New York and shall be binding upon the successors and assigns of each party hereto. The Holder
and the Company hereby mutually waive trial by jury and consent to exclusive jurisdiction and venue in the courts of the State
of New York or in the Federal courts sitting in the county or city of New York. This Agreement may be executed in counterparts,
and the facsimile transmission of an executed counterpart to this Agreement shall be effective as an original.

    	 	 	 

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Note to be duly executed by an officer thereunto duly authorized.

 

Dated:
03/13/2019

 

	 	 	TAURIGA
    SCIENCES, INC.
	 	 	 
	 	By:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]